Novavax Inc. (NASDAQ:NVAX) shares traded 0.65% higher at $17.03 on Wall Street last session.
In accordance with the data, 6 analysts cover Novavax Inc. (NASDAQ:NVAX). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $90.00 and a low of $16.00, we find $55.00. Given the previous closing price of $16.92, this indicates a potential upside of 225.06 percent. NVAX stock price is now -19.91% away from the 50-day moving average and -64.97% away from the 200-day moving average. The market capitalization of the company currently stands at $1.41B.
It has been rated a hold by 1 analysts and a buy by 3. Brokers who have rated the stock have averaged $52.40 as their price target over the next twelve months.
With the price target reduced from $132 to $27, JP Morgan Downgraded its rating from Neutral to Underweight for Novavax Inc. (NASDAQ: NVAX). On May 20, 2022, BofA Securities recently initiated its ‘Underperform’ rating on the stock quoting a target price of $35, while ‘B. Riley Securities’ rates the stock as ‘Buy’.
In other news, YOUNG JAMES F, Director sold 12,500 shares of the company’s stock on Mar 31. The stock was sold for $919,765 at an average price of $73.58. Upon completion of the transaction, the Director now directly owns 62,590 shares in the company, valued at $1.07 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 03, EVP, Chief Legal Officer Herrmann John A III sold 5,000 shares of the business’s stock. A total of $704,534 was realized by selling the stock at an average price of $140.91. This leaves the insider owning 3,845 shares of the company worth $65480.35. Insiders disposed of 72,808 shares of company stock worth roughly $1.24 million over the past 1 year. A total of 0.30% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in NVAX stock. A new stake in Novavax Inc. shares was purchased by RENAISSANCE TECHNOLOGIES LLC during the first quarter worth $14,996,000. WALLEYE CAPITAL LLC invested $1,281,000 in shares of NVAX during the first quarter. In the first quarter, WOLVERINE ASSET MANAGEMENT LLC acquired a new stake in Novavax Inc. valued at approximately $1,108,000. HRT FINANCIAL LP acquired a new stake in NVAX for approximately $1,028,000. SEVEN EIGHT CAPITAL, LP purchased a new stake in NVAX valued at around $437,000 in the second quarter. In total, there are 451 active investors with 46.90% ownership of the company’s stock.
During the past 12 months, Novavax Inc. has had a low of $16.00 and a high of $236.50. The fifty day moving average price for NVAX is $20.95 and a two-hundred day moving average price translates $48.05 for the stock.
The latest earnings results from Novavax Inc. (NASDAQ: NVAX) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$6.53, missing analysts’ expectations of $5.5 by -12.03. This compares to -$4.31 EPS in the same period last year. The net profit margin was -71.60% and return on equity was 416.60% for NVAX. The company reported revenue of $734.58 million for the quarter, compared to $178.84 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 310.74 percent. For the current quarter, analysts expect NVAX to generate $586.25M in revenue.
Novavax Inc.(NVAX) Company Profile
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company’s vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.